Literature DB >> 6330342

Degradation kinetics in aqueous solution of cefotaxime sodium, a third-generation cephalosporin.

H Fabre, N H Eddine, G Berge.   

Abstract

The degradation kinetics of a 3- acetoxymethylcephalosporin , cefotaxime sodium salt, in aqueous solution investigated by HPLC under different conditions (pH, ionic strength, temperature) and using different buffers. The scheme of degradation involves a cleavage of the beta-lactam nucleus and the deacetylation of the side chain. In highly acidic medium, the deacetylated derivative is easily converted to the lactone. The degradation rate constants were calculated at three pH values (1.9, 4.0, and 9.0) by measuring the residual cephalosporin and the main decomposition products. The degradation pathway is both supported by the results of a primary salt effect and by the agreement between the theoretical pH-rate profile and the experimental values. In the pH range from 3.0 to 7.0, the main process is a slow water-catalyzed or spontaneous cleavage of the beta-lactam nucleus with intramolecular participation of the side chain amido fraction in the 7-position. In alkaline or strongly acidic medium, the hydrolysis is a base- or acid-catalyzed reaction. Of the buffer systems investigated, carbonate buffer (pH 8.5) and borate buffers (pH 9.5 and 10.0) are found to increase the degradation rates, while acetate buffer decreases the degradation rates. The apparent activation energies determined at different pH values are compatible with a solvolysis mechanism and similar to those previously given in the literature for other cephalosporins. Cefotaxime in aqueous solution is slightly less stable than the main cephalosporin derivatives, despite its high resistance to the beta-lactamases and its remarkable biological activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330342     DOI: 10.1002/jps.2600730508

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Negative Epistasis and Evolvability in TEM-1 β-Lactamase--The Thin Line between an Enzyme's Conformational Freedom and Disorder.

Authors:  Eynat Dellus-Gur; Mikael Elias; Emilia Caselli; Fabio Prati; Merijn L M Salverda; J Arjan G M de Visser; James S Fraser; Dan S Tawfik
Journal:  J Mol Biol       Date:  2015-05-22       Impact factor: 5.469

2.  Effect of acetate and carbonate buffers on the photolysis of riboflavin in aqueous solution: a kinetic study.

Authors:  Iqbal Ahmad; Zubair Anwar; Kefi Iqbal; Syed Abid Ali; Tania Mirza; Adeela Khurshid; Aqeela Khurshid; Adeel Arsalan
Journal:  AAPS PharmSciTech       Date:  2014-02-07       Impact factor: 3.246

Review 3.  Penicillins and cephalosporins. Physicochemical properties and analysis in pharmaceutical and biological matrices.

Authors:  P C Van Krimpen; W P Van Bennekom; A Bult
Journal:  Pharm Weekbl Sci       Date:  1987-02-20

4.  Influence of temperature on degradation kinetics of ceftriaxone in diluted and undiluted human serum.

Authors:  M J Esteban; E Cantón; F Rius
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Cefotaxime stability during in vitro microbiological testing.

Authors:  C R Marchbanks; R L Yost; R L White
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Mixed Micelles Loaded with Bile Salt: An Approach to Enhance Intestinal Transport of the BCS Class III Drug Cefotaxime in Rats.

Authors:  Mosab Arafat; Cathrin Kirchhoefer; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

7.  Applying ecological resistance and resilience to dissect bacterial antibiotic responses.

Authors:  Hannah R Meredith; Virgile Andreani; Helena R Ma; Allison J Lopatkin; Anna J Lee; Deverick J Anderson; Gregory Batt; Lingchong You
Journal:  Sci Adv       Date:  2018-12-05       Impact factor: 14.136

8.  Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat.

Authors:  Svetlana Golocorbin-Kon; Momir Mikov; Mousab Arafat; Zika Lepojevic; Ivan Mikov; Majda Sahman-Zaimovic; Zdenko Tomic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.